Whole Versus Partial Vertebral Body IMRT for Spinal Metastases
NCT ID: NCT02972229
Last Updated: 2016-11-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2016-11-30
2019-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary endpoint was the time to pain relief. Secondary endpoints were quality of life (QoL), fatigue, pain, overall survival, bone survival, local control, pathological fracture, pain-free internal and neurological deficit. The baseline examination shall be carried out on the first day of radiotherapy prior to the start of therapy and is scheduled to comprise the comprehensive recording of the sociodemographic data, the recording of the current pain situation, the quality of life, and the current degree of fatigue. The follow-up examinations shall take place at each follow up visit , measuring those parameters recorded at the baseline examination. The further follow-up examinations shall correspond to those carried out as standard after-care investigations.
The secondary endpoints such as fatigue and quality of life shall be recorded using validated questionnaires (EORTC QLQ FA13 and EORTC QLQ BM22. All patients will also be asked to record their pain history using a pain diary (documentation of medication daily during treatment, once weekly after the end of treatment, VAS pain scale). Furthermore, the local control was assessed by means of CT images taken prior to, three and six months after RT. The pain response was documented on the VAS (range 0-10). Complete response (CR) was defined as VAS = 0 after three and six months, partial response (PR) as an improvement by at least two score points after three and six months. Overall survival (OS) was defined as time from initial diagnosis until death, bone survival as time from initial diagnosis of spinal bone metastasis until death.
In each case, the treatment plan was designed based on tumor geometry, proximity to the spinal cord, and location. The planning tumor volume (PTV) was defined as equal to gross tumor volume (GTV). The spinal cord, cauda equina, nerve roots, and bowel were contoured as organs at risk (OARs) and critical structures. An inverse treatment planning method along with a linear optimization algorithm were employed. The target volume was designated to include either the GTV and the entire vertebral body (WB group) or only the GTV (PB group) at each spinal level.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
partial body group
10x(3-5) Gy IMRT on partial vertebral body
10x(3-5) Gy IMRT
10x(3-5) Gy IMRT on partial vertebral body for spinal metastases
whole body group
10x3 Gy IMRT on whole vertebral body
10x3 Gy IMRT
10x3 Gy IMRT on whole vertebral body for spinal metastases
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
10x(3-5) Gy IMRT
10x(3-5) Gy IMRT on partial vertebral body for spinal metastases
10x3 Gy IMRT
10x3 Gy IMRT on whole vertebral body for spinal metastases
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Indication for RT of the spinal bone metastases
* Maximal two irradiated vertebral-bodies per region
* Maximal two different vertebral regions
* Age: between 18 and 80 years
* Karnofsky index (10) ≥ 70
* Signed Declaration of Informed Consent
* Tumor distance \> 3 mm to myelon
Exclusion Criteria
* Significant neurological or psychiatric disorders, including dementia and epileptic seizures
* Earlier RT at the current irradiated site
* Other severe disorders that in the judgement of the study director may prevent the patient's participation in the study
* Lacking or diminished legal capacity
* Any medical of psychological condition that the study director considers a preventive factor for the patient's ability to complete the study or to adequately
* understand the scope of the study and to give his/her consent
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhenwei Zou
Principal Investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WuhanUH201610
Identifier Type: -
Identifier Source: org_study_id